Depression-an Underrecognized Target for Prevention of Dementia in Alzheimer's Disease

Overview

Journal Transl Psychiatry

Specialties Psychiatry
Public Health

Date 2020 May 21

PMID 32433512

Citations 105

Authors

Forugh S Dafsari

Frank Jessen

Affiliations

Soon will be listed here.

Abstract

It is broadly acknowledged that the onset of dementia in Alzheimer's disease (AD) may be modifiable by the management of risk factors. While several recent guidelines and multidomain intervention trials on prevention of cognitive decline address lifestyle factors and risk diseases, such as hypertension and diabetes, a special reference to the established risk factor of depression or depressive symptoms is systematically lacking. In this article we review epidemiological studies and biological mechanisms linking depression with AD and cognitive decline. We also emphasize the effects of antidepressive treatment on AD pathology including the molecular effects of antidepressants on neurogenesis, amyloid burden, tau pathology, and inflammation. We advocate moving depression and depressive symptoms into the focus of prevention of cognitive decline and dementia. We constitute that early treatment of depressive symptoms may impact on the disease course of AD and affect the risk of developing dementia and we propose the need for clinical trials.

Citing Articles

Altered triple network model connectivity is associated with cognitive function and depressive symptoms in older adults.

Kolobaric A, Andreescu C, Gerlach A, Jasarevic E, Aizenstein H, Pascoal T Alzheimers Dement. 2025; 21(3):e14493.

PMID: 40042417 PMC: 11881620. DOI: 10.1002/alz.14493.

Structural variants linked to Alzheimer's disease and other common age-related clinical and neuropathologic traits.

Vialle R, de Paiva Lopes K, Li Y, Ng B, Schneider J, Buchman A Genome Med. 2025; 17(1):20.

PMID: 40038788 PMC: 11881306. DOI: 10.1186/s13073-025-01444-6.

Alzheimer's disease with depression: clinical characteristics and potential mechanisms involving orexin and brain atrophy.

Li J, Lian T, Li J, Wei N, Guo P, He M Transl Psychiatry. 2025; 15(1):66.

PMID: 39994172 PMC: 11850912. DOI: 10.1038/s41398-025-03251-4.

A bibliometric analysis of research on dementia comorbid with depression from 2005 to 2024.

Li X, Su W, Cai L Front Neurosci. 2025; 19:1508662.

PMID: 39981405 PMC: 11841476. DOI: 10.3389/fnins.2025.1508662.

Successful aging was negatively associated with depression and anxiety symptoms among adults aged 65 years and older in Ningbo, China.

Li L, Yang H, Gao Y, Yan W, Yuan Y, Lian G BMC Psychiatry. 2025; 25(1):115.

PMID: 39934673 PMC: 11817734. DOI: 10.1186/s12888-025-06566-0.

References

Gatchel J, Donovan N, Locascio J, Schultz A, Becker J, Chhatwal J . Depressive Symptoms and Tau Accumulation in the Inferior Temporal Lobe and Entorhinal Cortex in Cognitively Normal Older Adults: A Pilot Study. J Alzheimers Dis. 2017; 59(3):975-985. PMC: 5577564. DOI: 10.3233/JAD-170001. View

Singh-Manoux A, Dugravot A, Fournier A, Abell J, Ebmeier K, Kivimaki M . Trajectories of Depressive Symptoms Before Diagnosis of Dementia: A 28-Year Follow-up Study. JAMA Psychiatry. 2017; 74(7):712-718. PMC: 5710246. DOI: 10.1001/jamapsychiatry.2017.0660. View

Jansen W, Ossenkoppele R, Knol D, Tijms B, Scheltens P, Verhey F . Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA. 2015; 313(19):1924-38. PMC: 4486209. DOI: 10.1001/jama.2015.4668. View

Caraci F, Pappalardo G, Basile L, Giuffrida A, Copani A, Tosto R . Neuroprotective effects of the monoamine oxidase inhibitor tranylcypromine and its amide derivatives against Aβ(1-42)-induced toxicity. Eur J Pharmacol. 2015; 764:256-263. DOI: 10.1016/j.ejphar.2015.07.015. View

Dranovsky A, Hen R . Hippocampal neurogenesis: regulation by stress and antidepressants. Biol Psychiatry. 2006; 59(12):1136-43. PMC: 7537828. DOI: 10.1016/j.biopsych.2006.03.082. View

Budas G, Coughlan C, Seckl J, Breen K . The effect of corticosteroids on amyloid beta precursor protein/amyloid precursor-like protein expression and processing in vivo. Neurosci Lett. 1999; 276(1):61-4. DOI: 10.1016/s0304-3940(99)00790-9. View

Wang Y, Ren Q, Gong W, Wu D, Tang X, Li X . Escitalopram attenuates β-amyloid-induced tau hyperphosphorylation in primary hippocampal neurons through the 5-HT1A receptor mediated Akt/GSK-3β pathway. Oncotarget. 2016; 7(12):13328-39. PMC: 4924645. DOI: 10.18632/oncotarget.7798. View

Byers A, Yaffe K . Depression and risk of developing dementia. Nat Rev Neurol. 2011; 7(6):323-31. PMC: 3327554. DOI: 10.1038/nrneurol.2011.60. View

Malberg J, Eisch A, Nestler E, Duman R . Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J Neurosci. 2000; 20(24):9104-10. PMC: 6773038. View

10.

Felger J, Lotrich F . Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications. Neuroscience. 2013; 246:199-229. PMC: 3741070. DOI: 10.1016/j.neuroscience.2013.04.060. View

11.

Frodl T, OKeane V . How does the brain deal with cumulative stress? A review with focus on developmental stress, HPA axis function and hippocampal structure in humans. Neurobiol Dis. 2012; 52:24-37. DOI: 10.1016/j.nbd.2012.03.012. View

12.

Anacker C, Zunszain P, Cattaneo A, Carvalho L, Garabedian M, Thuret S . Antidepressants increase human hippocampal neurogenesis by activating the glucocorticoid receptor. Mol Psychiatry. 2011; 16(7):738-50. PMC: 3121947. DOI: 10.1038/mp.2011.26. View

13.

Minakawa E, Miyazaki K, Maruo K, Yagihara H, Fujita H, Wada K . Chronic sleep fragmentation exacerbates amyloid β deposition in Alzheimer's disease model mice. Neurosci Lett. 2017; 653:362-369. DOI: 10.1016/j.neulet.2017.05.054. View

14.

Li Y, Zhang Y, Liu Y, Wang H, Yuan L, Luo Z . Moclobemide up-regulates proliferation of hippocampal progenitor cells in chronically stressed mice. Acta Pharmacol Sin. 2004; 25(11):1408-12. View

15.

Green R, Cupples L, Kurz A, Auerbach S, Go R, Sadovnick D . Depression as a risk factor for Alzheimer disease: the MIRAGE Study. Arch Neurol. 2003; 60(5):753-9. DOI: 10.1001/archneur.60.5.753. View

16.

Lyketsos C, DelCampo L, Steinberg M, Miles Q, Steele C, Munro C . Treating depression in Alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS. Arch Gen Psychiatry. 2003; 60(7):737-46. DOI: 10.1001/archpsyc.60.7.737. View

17.

Snowden M, Atkins D, Steinman L, Bell J, Bryant L, Copeland C . Longitudinal Association of Dementia and Depression. Am J Geriatr Psychiatry. 2014; 23(9):897-905. PMC: 4369182. DOI: 10.1016/j.jagp.2014.09.002. View

18.

Gallagher D, Kiss A, Lanctot K, Herrmann N . Depression and Risk of Alzheimer Dementia: A Longitudinal Analysis to Determine Predictors of Increased Risk among Older Adults with Depression. Am J Geriatr Psychiatry. 2018; 26(8):819-827. PMC: 6101977. DOI: 10.1016/j.jagp.2018.05.002. View

19.

Sheline Y, Gado M, Kraemer H . Untreated depression and hippocampal volume loss. Am J Psychiatry. 2003; 160(8):1516-8. DOI: 10.1176/appi.ajp.160.8.1516. View

20.

Diniz B, Butters M, Albert S, Dew M, Reynolds 3rd C . Late-life depression and risk of vascular dementia and Alzheimer's disease: systematic review and meta-analysis of community-based cohort studies. Br J Psychiatry. 2013; 202(5):329-35. PMC: 3640214. DOI: 10.1192/bjp.bp.112.118307. View